Publicaciones en colaboración con investigadores/as de Klinikum der Universität München (31)

2024

  1. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  2. Dual disorder: does expert clinical experience support the rationale for cariprazine use?

    European Review for Medical and Pharmacological Sciences, Vol. 28, Núm. 5, pp. 2095-2106

  3. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Identifying Early Infections in the Setting of CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

    HemaSphere, Vol. 7, Núm. 4, pp. E858

  3. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

    Blood

  4. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

    American Journal of Hematology, Vol. 98, Núm. 11, pp. 1699-1710

2022

  1. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

    Annals of Oncology, Vol. 33, Núm. 3, pp. 259-275

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  3. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

    Blood Advances

  4. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 9, pp. 2194-2202

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype

    EMBO Molecular Medicine, Vol. 13, Núm. 10

  4. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491

2020

  1. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study

    British Journal of Haematology, Vol. 188, Núm. 5, pp. 745-756

  2. Prognostic gene expression signature for high-grade serous ovarian cancer

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250

2018

  1. Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes

    Journal of the American College of Cardiology, Vol. 71, Núm. 3, pp. 279-288

  2. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Leukemia, Vol. 32, Núm. 8, pp. 1799-1803

2017

  1. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

    Leukemia and Lymphoma, Vol. 58, Núm. 12, pp. 2824-2832